Parkinson disease: electrophysiological (CNV) analysis related to pharmacological treatment.
The contingent negative variation (CNV) was studied in a group of patients with Parkinson's disease. Testing was carried out 3 times: after a pharmacological wash-out period and at 15 and 30 days after the start of treatment with L-DOPA and bromocriptine. Peak and area CNV increased significantly after each treatment. The post-imperative negative variation (PINV) was observed in 6 out of 10 patients. The correlation found between electrophysiological functioning (CNV) measures and pharmacological treatment supports the view that dopaminergic brain activity mediates the generation of the slow negative event-related brain potentials.
D001971:Bromocriptine / Q000627:therapeutic use*; D003265:Contingent Negative Variation / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*
D001971:Bromocriptine; D007980:Levodopa